Xeris Biopharma shares surged nearly 29% after quarterly revenue rose 44%, Recorlev sales nearly doubled, profitability improved and the company raised its financial targets.
Tony Jackson
Nov 06, 2026
ADMA Biologics shares rose 23% after the company reported stronger third-quarter profit, record gross margins and raised full-year earnings guidance, driven by Asceniv growth.
Tony Jackson
Nov 06, 2026
Vericel reported record third-quarter revenue of $85.4 million, a sharp rise in net income and stronger full-year guidance, sending its shares 21% higher.
Mike Claire
Nov 06, 2026
Neuren Pharmaceuticals shares rose nearly 17% after stronger Daybue sales and a US$35 million milestone payment prompted the company to raise its 2026 royalty income guidance.
Tony Jackson
Nov 05, 2026
LivaNova shares rose nearly 17% after the medical technology company reported double-digit growth in both main businesses, beat adjusted earnings expectations and raised its 2026 outlook.
Mike Claire
Nov 05, 2026
CareDx shares surged after the transplant diagnostics company beat third-quarter expectations, reported stronger testing growth and raised its 2026 revenue and adjusted EBITDA forecasts.
Mike Claire
Nov 03, 2026
Regeneron shares reached a 52-week high after quarterly profit and revenue exceeded forecasts, helped by stronger Dupixent partnership earnings and record sales of key medicines.
Tony Jackson
Nov 03, 2026
CareDx shares climbed nearly 24% after third-quarter revenue rose 39% to $139 million, prompting the transplant diagnostics company to raise its 2026 revenue and adjusted EBITDA forecasts.
Tony Jackson
Oct 31, 2026
BrightSpring Health Services shares rose nearly 16% after third-quarter revenue and profit exceeded expectations, while the company raised its 2026 outlook and reported lower leverage.
Tony Jackson
Oct 31, 2026
Mesoblast shares surged in Australia and the US after Ryoncil revenue rose 44%, quarterly cash spending fell sharply and the company reported progress on adult trials and pipeline treatments.
Tony Jackson
Oct 30, 2026
Bausch Health shares rose 17% after the drugmaker reported strong third-quarter results, raised its 2026 guidance and reduced net debt, despite future Medicare pricing risks.
Mike Claire
Oct 30, 2026
Glaukos shares surged after the eye-care company reported record third-quarter sales, raised its 2026 forecast and outlined a preliminary $1 billion revenue target for 2027.
Tony Jackson
Oct 30, 2026
Neuren Pharmaceuticals shares gained 6.3% as investors focused on potential milestone payments, DAYBUE sales growth, European expansion and upcoming Japanese trial results for trofinetide.
Mike Claire
Oct 29, 2026
Mesoblast shares jumped 23.4% after quarterly Ryoncil revenue rose 44% to US$28 million and operational cash spending fell 86% to US$2.1 million.
Mike Claire
Oct 29, 2026
Axogen shares rose nearly 22% after the nerve repair company exceeded third-quarter earnings and revenue expectations, raised its 2026 sales forecast and reported progress on insurance coverage.
Tony Jackson
Oct 29, 2026
Genmab shares rose 16% after encouraging ovarian and colorectal cancer trial results, a JPMorgan upgrade and stronger expectations for its experimental drug pipeline.
Mike Claire
Oct 29, 2026
Kiniksa Pharmaceuticals raised its 2026 Arcalyst revenue forecast to as much as $1.05 billion after quarterly sales of the recurrent pericarditis drug rose 58%.
Mike Claire
Oct 28, 2026
PYC Therapeutics shares rose 9.4% after a recent decline, with investors assessing early PYC-003 data and awaiting further results from the biotech's kidney disease trial.
Tony Jackson
Oct 27, 2026
Surgery Partners shares jumped nearly 46% after HealthSpan Partners agreed to acquire the outpatient surgery operator for about $5.7 billion, including debt, in an all-cash deal.
Tony Jackson
Oct 27, 2026
Xencor shares rose nearly 20% after early data showed its experimental kidney cancer drug produced tumour shrinkage in 45.5% of 11 evaluable patients.
Mike Claire
Oct 27, 2026
Oruka Therapeutics shares rose after its experimental psoriasis treatment produced complete skin clearance in 61% of patients receiving the highest dose in a Phase 2b trial.
Mike Claire
Oct 27, 2026
Robert Half shares rose more than 14% after quarterly earnings increased, its staffing division returned to growth and the company forecast stronger fourth-quarter profit amid cautious hiring demand.
Tony Jackson
Oct 24, 2026
Celcuity shares rose nearly 8% after Cantor Fitzgerald initiated coverage with an overweight rating, citing Revtorpyk's growth potential ahead of new breast cancer trial data.
Mike Claire
Oct 23, 2026
Biohaven shares rose nearly 30% after the FDA accepted a resubmitted application for Vyglxia, an experimental treatment for spinocerebellar ataxia previously rejected over efficacy concerns.
Mike Claire
Oct 23, 2026
Telix Pharmaceuticals shares fell sharply after third-quarter revenue growth showed no acceleration, despite strong demand for imaging products and progress in its cancer pipeline.
Tony Jackson
Oct 22, 2026
Telix Pharmaceuticals shares fell 6.6% to A$14.72, extending a volatile period as investors weigh strong revenue growth against rising costs, valuation concerns and regulatory risks.
Mike Claire
Oct 21, 2026
Disc Medicine shares rose sharply after the company reported positive Phase 3 results for bitopertin in erythropoietic protoporphyria, while seeking a renewed FDA review.
Mike Claire
Oct 20, 2026
TAL Dai-ichi Life Australia has proposed acquiring the remaining stake in Challenger for A$7.94 billion, but the indicative offer still requires due diligence, regulatory clearance and board approval.
Hannah Kim
Oct 19, 2026
Hims & Hers has launched Hers in Australia, replacing Eucalyptus venture Juniper and expanding access to locally supervised telehealth services for women, including menopause and weight management care.
Hannah Kim
Oct 15, 2026
Liquidia shares jumped after the drugmaker agreed to pay United Therapeutics $380.7 million, ending six lawsuits and securing continued sales of Yutrepia for PAH.
Tony Jackson
Oct 15, 2026